Future

Improving Care & Driving Research

Nov 30 - Dec 3, 2023 - Austin, TX

Industry Science Presentations

Time Event Location
Friday, December 1st, 2023
10:00am – 10:30am Sage Therapeutics
Parkinson’s Disease Mild Cognitive Impairment: SAGE-718, a Novel Investigational Oral NMDA Receptor Positive Allosteric Modulator.
Presented by Amy Bullock.
Lonestar East Foyer, 3rd floor
3:30pm – 4:00pm Acadia Pharmaceuticals
Recent NUPLAZID® (pimavanserin) Label Clarification.
The update clarifies that patients with Parkinson’s disease disease-related hallucinations and delusions who also have dementia are an approved patient population for NUPLAZID and are subsumed within the approved indication. This talk will discuss the reason for the update and data to support this change.
Presented by Victor Abler, VP of Medical Affairs.
Lonestar East Foyer, 3rd floor
Saturday, December 2nd, 2023
7:00am-7:30am Amneal Pharmaceuticals
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation.
Presented by Stanley Fisher, Vice President of Medical Affairs.
Room 201-202
7:30am-8:00am Aspen Neuroscience
Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine beginning with Parkinson's Disease.
Aspen's development of patient-derived iPSCs to create personalized cell therapies that address diseases with high unmet medical needs, focusing on autologous neuron replacement for PD.
Presented by President and Chief Executive Officer Damien McDevitt.
Room 201-202
10:00am – 10:30am Supernus Pharmaceuticals
Supernus will review Continuous Subcutaneous Apomorphine Infusion including an overview of the apomorphine compound and pharmacology, clinical development, and dispelling certain myths about apomorphine.
Presentation will be given by Mindy Grall, Senior Director, Medical Affairs.
Lonestar East Foyer, 3rd floor
1:00pm – 1:30pm AbbVie Pharmaceuticals
Advancing Parkinson’s Disease: The Consequences of Inaction: The challenges associated with oral medications as Parkinson’s disease progresses, understanding the burden of progressive disease, and the importance of advancing therapy to ease the burden for your patients.
Presented by Pav Kukreja, Senior Scientific Director.
Lonestar East Foyer, 3rd floor
3:30pm – 4:00pm BlueRock Therapeutics
Dopaminergic neuronal precursor cell therapy for Parkinson’s disease: Background and 1-year results from a Phase 1 study of bemdaneprocel.
Presented by Marcus Yountz, VP of Clinical Development.
Lonestar East Foyer, 3rd floor